Follow the Coeptis Therapeutics Holdings, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 17 January 2024 (Acquisition). Among the most active insiders: Mehalick David. Every trade is openly available.
9
Insider Decl.
n/a
Thresholds
€57,476
8 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Coeptis Therapeutics Holdings, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
52Σ signal
Buys €57,476n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,659 of 27,612 companies
37.5
score / 100
Value
23
Quality
52
FCF yld-4.3%
Earn yld-5.5%
EV/EBITDA·
ROE-28%
Gross mgn87%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
28,638 shares@ US$0.9176.7% of flowCommon StockSEC:0001683168-23-006169:0
Canonical exit: 23 Nov 2023 (T+90)
9 of 9 declarations
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc. is a company focused on developing innovative therapies for cancer treatment. It is listed on NASDAQ under the ticker COEP.